Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Multiple Sclerosis (MS) - Relapsing-remitting

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Georgia State University, Atlanta, Georgia, United States
Contact: Study coordinator (Feng Yang, PhD) · fyang@gsu.edu · 404-413-8357
Contact: Principal Investigator (Feng Yang, PhD)
Atlanta Neuroscience Institute, Atlanta, Georgia, United States
Contact: Study coordinator (Joash Lazarus, MD) · jtlazarus@atlneuroinstitute.org · 404-351-0205
Contact: Principal Investigator (Joash Lazarus, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)Recruiting

Baltimore, United States

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Multiple Sclerosis · Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)RecruitingPHASE4

Chicago, United States

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Multiple Sclerosis (MS) · Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Primary Progressive

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Francisco, United States

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)Recruiting

Nice, France · Nîmes, France